Shanghai Junshi Biosciences soars 21 percent on HK debut

By Julia Fioretti

HONG KONG: Chinese biotech startup Shanghai Junshi Biosciences Co Ltd soared more than 21 percent in its Hong Kong debut on Monday after raising $394 million in its IPO, a rare strong showing by a biotech company in the financial hub.

Shares opened at HK$23.50 ($3.00), 21.3 percent higher than the initial public offering price (IPO) of HK$19.38. That makes its performance the best so far among biotech companies that have listed in Hong Kong, which earlier this year changed its rules to allow listings from pre-revenue biotechs.

Innovent Biologics’s stock leapt almost 20 percent on its listing in October, boosting hopes for the sector after the first few companies plunged below their IPO prices.

Hong Kong has enjoyed its best year since 2010 in terms of listings, with companies raising $36.3 billion, more than anywhere else in the world.

But performance has been poor, with many of the big-ticket listings trading below their IPO prices.

Shanghai-based Junshi Biosciences has a pipeline of 13 biologic drug candidates, including immuno-oncology drugs and drugs targeting metabolic and inflammation or autoimmune diseases, its listing prospectus showed.

Its JS001 or toripalimab, which treats patients with unresectable or metastatic melanoma who have failed previous systemic therapies, won China’s first approval for a home-grown PD-1 monoclonal antibody.

CICC was the sole sponsor for the float. Along with Citi and Credit Suisse, the Chinese bank is also among joint bookrunners. ch)

  • Related Posts

    • Pharma
    • July 24, 2025
    • 76 views
    Natco Pharma shares dip over 2% after Rs 2,000-crore stake buy in South Africa’s Adcock Ingram

    Natco Pharma shares slipped 2.5% to Rs 1,009 apiece on the BSE in Thursday’s trade after the company announced its plan to acquire a 35.75% stake in South Africa-based Adcock…

    • Pharma
    • July 22, 2025
    • 173 views
    DGFT Extends Deadline on Application for Export of Pharma Grade Sugar

    The Directorate General of Foreign Trade ( DGFT ) has notified an extension in the deadline for submitting applications for the export of Pharma Grade Sugar. This was communicated through Trade Notice…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Natco Pharma shares dip over 2% after Rs 2,000-crore stake buy in South Africa’s Adcock Ingram

    Natco Pharma shares dip over 2% after Rs 2,000-crore stake buy in South Africa’s Adcock Ingram

    10, 000 Km is just a Number for Intercontinental Tele Surgery by SSIMantra

    10, 000 Km is just a Number for Intercontinental Tele Surgery by SSIMantra

    DGFT Extends Deadline on Application for Export of Pharma Grade Sugar

    DGFT Extends Deadline on Application for Export of Pharma Grade Sugar

    Bihar Healthcare is poised to be embraced by Robotic Surgery Mantra

    Bihar Healthcare is poised to be embraced by Robotic Surgery Mantra